106 related articles for article (PubMed ID: 37884300)
1. Radiogenomics Provides Insights into Gliomas Demonstrating Single-Arm 1p or 19q Deletion.
Lasocki A; Buckland ME; Molinaro T; Xie J; Gaillard F
AJNR Am J Neuroradiol; 2023 Nov; 44(11):1270-1274. PubMed ID: 37884300
[TBL] [Abstract][Full Text] [Related]
2. MRI Scoring Systems for Predicting Isocitrate Dehydrogenase Mutation and Chromosome 1p/19q Codeletion in Adult-type Diffuse Glioma Lacking Contrast Enhancement.
Kang KM; Song J; Choi Y; Park C; Park JE; Kim HS; Park SH; Park CK; Choi SH
Radiology; 2024 May; 311(2):e233120. PubMed ID: 38713025
[TBL] [Abstract][Full Text] [Related]
3. Comparison of diagnostic performance of radiologist- and AI-based assessments of T2-FLAIR mismatch sign and quantitative assessment using synthetic MRI in the differential diagnosis between astrocytoma, IDH-mutant and oligodendroglioma, IDH-mutant and 1p/19q-codeleted.
Kikuchi K; Togao O; Yamashita K; Momosaka D; Kikuchi Y; Kuga D; Yuhei S; Fujioka Y; Narutomi F; Obara M; Yoshimoto K; Ishigami K
Neuroradiology; 2024 Mar; 66(3):333-341. PubMed ID: 38224343
[TBL] [Abstract][Full Text] [Related]
4. TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations.
Arita H; Matsushita Y; Machida R; Yamasaki K; Hata N; Ohno M; Yamaguchi S; Sasayama T; Tanaka S; Higuchi F; Iuchi T; Saito K; Kanamori M; Matsuda KI; Miyake Y; Tamura K; Tamai S; Nakamura T; Uda T; Okita Y; Fukai J; Sakamoto D; Hattori Y; Pareira ES; Hatae R; Ishi Y; Miyakita Y; Tanaka K; Takayanagi S; Otani R; Sakaida T; Kobayashi K; Saito R; Kurozumi K; Shofuda T; Nonaka M; Suzuki H; Shibuya M; Komori T; Sasaki H; Mizoguchi M; Kishima H; Nakada M; Sonoda Y; Tominaga T; Nagane M; Nishikawa R; Kanemura Y; Kuchiba A; Narita Y; Ichimura K
Acta Neuropathol Commun; 2020 Nov; 8(1):201. PubMed ID: 33228806
[TBL] [Abstract][Full Text] [Related]
5. Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status.
Delfanti RL; Piccioni DE; Handwerker J; Bahrami N; Krishnan A; Karunamuni R; Hattangadi-Gluth JA; Seibert TM; Srikant A; Jones KA; Snyder VS; Dale AM; White NS; McDonald CR; Farid N
J Neurooncol; 2017 Dec; 135(3):601-609. PubMed ID: 28871469
[TBL] [Abstract][Full Text] [Related]
6. Quantification of T2-FLAIR Mismatch in Nonenhancing Diffuse Gliomas Using Digital Subtraction.
Cho NS; Sanvito F; Le VL; Oshima S; Teraishi A; Yao J; Telesca D; Raymond C; Pope WB; Nghiemphu PL; Lai A; Cloughesy TF; Salamon N; Ellingson BM
AJNR Am J Neuroradiol; 2024 Feb; 45(2):188-197. PubMed ID: 38238098
[TBL] [Abstract][Full Text] [Related]
7. Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT.
Pekmezci M; Rice T; Molinaro AM; Walsh KM; Decker PA; Hansen H; Sicotte H; Kollmeyer TM; McCoy LS; Sarkar G; Perry A; Giannini C; Tihan T; Berger MS; Wiemels JL; Bracci PM; Eckel-Passow JE; Lachance DH; Clarke J; Taylor JW; Luks T; Wiencke JK; Jenkins RB; Wrensch MR
Acta Neuropathol; 2017 Jun; 133(6):1001-1016. PubMed ID: 28255664
[TBL] [Abstract][Full Text] [Related]
8. Association of partial T2-FLAIR mismatch sign and isocitrate dehydrogenase mutation in WHO grade 4 gliomas: results from the ReSPOND consortium.
Lee MD; Patel SH; Mohan S; Akbari H; Bakas S; Nasrallah MP; Calabrese E; Rudie J; Villanueva-Meyer J; LaMontagne P; Marcus DS; Colen RR; Balana C; Choi YS; Badve C; Barnholtz-Sloan JS; Sloan AE; Booth TC; Palmer JD; Dicker AP; Flanders AE; Shi W; Griffith B; Poisson LM; Chakravarti A; Mahajan A; Chang S; Orringer D; Davatzikos C; Jain R;
Neuroradiology; 2023 Sep; 65(9):1343-1352. PubMed ID: 37468750
[TBL] [Abstract][Full Text] [Related]
9. T2-FLAIR mismatch sign and machine learning-based multiparametric MRI radiomics in predicting IDH mutant 1p/19q non-co-deleted diffuse lower-grade gliomas.
Tang WT; Su CQ; Lin J; Xia ZW; Lu SS; Hong XN
Clin Radiol; 2024 May; 79(5):e750-e758. PubMed ID: 38360515
[TBL] [Abstract][Full Text] [Related]
10. Machine learning modeling of genome-wide copy number alteration signatures reliably predicts IDH mutational status in adult diffuse glioma.
Nuechterlein N; Shapiro LG; Holland EC; Cimino PJ
Acta Neuropathol Commun; 2021 Dec; 9(1):191. PubMed ID: 34863298
[TBL] [Abstract][Full Text] [Related]
11. Oligodendroglioma, IDH-mutant and 1p/19q-codeleted-prognostic factors, standard of care and chemotherapy, and future perspectives with neoadjuvant strategy.
Sasaki H; Kitamura Y; Toda M; Hirose Y; Yoshida K
Brain Tumor Pathol; 2024 Apr; 41(2):43-49. PubMed ID: 38564040
[TBL] [Abstract][Full Text] [Related]
12. T2-FLAIR Mismatch: An Imaging Biomarker for Children's
van Maren EA; Dankbaar JW; Wesseling P; Plasschaert S; Muhlebner A; Hoving EW; Robe PA; Snijders TJ; Hoogendijk R; Kranendonk MEG; Lequin MH
AJNR Am J Neuroradiol; 2024 Jun; 45(6):747-752. PubMed ID: 38724203
[TBL] [Abstract][Full Text] [Related]
13. Molecular and histologic characteristics of pseudoprogression in diffuse gliomas.
Lin AL; White M; Miller-Thomas MM; Fulton RS; Tsien CI; Rich KM; Schmidt RE; Tran DD; Dahiya S
J Neurooncol; 2016 Dec; 130(3):529-533. PubMed ID: 27704386
[TBL] [Abstract][Full Text] [Related]
14. Individualized discrimination of tumor progression from treatment-related changes in different types of adult-type diffuse gliomas using [
Chen Q; Wang K; Ren X; Zhao X; Chen Q; Fan D; Zhang S; Li X; Ai L
J Neurooncol; 2023 Dec; 165(3):547-559. PubMed ID: 38095773
[TBL] [Abstract][Full Text] [Related]
15. Molecular subtyping of tumors from patients with familial glioma.
Ruiz VY; Praska CE; Armstrong G; Kollmeyer TM; Yamada S; Decker PA; Kosel ML; Eckel-Passow JE; Lachance DH; Bainbridge MN; Melin BS; Bondy ML; Jenkins RB;
Neuro Oncol; 2018 May; 20(6):810-817. PubMed ID: 29040662
[TBL] [Abstract][Full Text] [Related]
16. A custom next-generation sequencing panel for 1p/19q codeletion and mutational analysis in gliomas.
Qi P; Yao QL; Lao IW; Ren M; Bai QM; Cai X; Xue T; Wei R; Zhou XY
J Neuropathol Exp Neurol; 2024 Mar; 83(4):258-267. PubMed ID: 38408388
[TBL] [Abstract][Full Text] [Related]
17. Predictors and early survival outcomes of maximal resection in WHO grade II 1p/19q-codeleted oligodendrogliomas.
Harary M; Kavouridis VK; Torre M; Zaidi HA; Chukwueke UN; Reardon DA; Smith TR; Iorgulescu JB
Neuro Oncol; 2020 Mar; 22(3):369-380. PubMed ID: 31538193
[TBL] [Abstract][Full Text] [Related]
18. Amide proton transfer weighted and diffusion weighted imaging based radiomics classification algorithm for predicting 1p/19q co-deletion status in low grade gliomas.
Ma A; Yan X; Qu Y; Wen H; Zou X; Liu X; Lu M; Mo J; Wen Z
BMC Med Imaging; 2024 Apr; 24(1):85. PubMed ID: 38600452
[TBL] [Abstract][Full Text] [Related]
19. Distinct patterns of 1p and 19q alterations identify subtypes of human gliomas that have different prognoses.
Vogazianou AP; Chan R; Bäcklund LM; Pearson DM; Liu L; Langford CF; Gregory SG; Collins VP; Ichimura K
Neuro Oncol; 2010 Jul; 12(7):664-78. PubMed ID: 20164239
[TBL] [Abstract][Full Text] [Related]
20. Patterns of T2-FLAIR discordance across a cohort of adult-type diffuse gliomas and deviations from the classic T2-FLAIR mismatch sign.
Malik P; Soliman R; Chen YA; Munoz DG; Das S; Bharatha A; Mathur S
Neuroradiology; 2024 Apr; 66(4):521-530. PubMed ID: 38347151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
